...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: What's going on with the Phase 2 ZEN-3694 mCRPC trial?

Based on past MD&A and Financial filings for Zenith over the past few years, they are on the near end of month schedule for March, August, September and December. So unlike Resverlogix, who is expected to release MD&A and financials by end of July, Zenith seems to be a month later.

BDAZ 

Share
New Message
Please login to post a reply